Novonesis (Novozymes) B (MEX:NSISN) Beta: 0.5829 (As of Jun. 25, 2026)


MEX:NSISN Novonesis (Novozymes) B MEX:NSISN
91 GF Score
Price MXN911.11
GF Value MXN979.45
! 3 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Beta?

Novonesis (Novozymes) B MEX:NSISN 91 Beta is 0.5829 as of Jun. 25, 2026. GuruFocus rates MEX:NSISN with a GF Score™ of 91/100 and a GF Value™ of MXN979.45. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Novonesis (Novozymes) B's Beta is 0.5829.


Novonesis (Novozymes) B  (MEX:NSISN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Novonesis (Novozymes) B Beta Related Terms


Novonesis (Novozymes) B Beta Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Beta Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.22 0.33 -0.01 0.11

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.14 0.01 0.11 0.54

MEX:NSISN vs LIN, SHW, ECL: Beta Comparison

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B Beta vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Beta distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Beta falls into.


MEX:NSISN
91GF Score
Novonesis (Novozymes) B MEX:NSISN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5829 mean?
Novonesis (Novozymes) B (MEX:NSISN) has a Beta of 0.5829 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Beta too high?
Novonesis (Novozymes) B's current Beta is 0.5829. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Beta compare to LIN and SHW?
Novonesis (Novozymes) B's Beta of 0.5829 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Chemicals company?
A good Beta depends on the Chemicals industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Beta is 0.5829. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current Beta of 0.5829. The stock's GF Value™ is MXN979.45, compared to a current price of MXN911.11 — trading 7% below its estimated fair value. The current Beta is 0.5829. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current Beta is 0.5829 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of MXN911.11 is trading 7% below its estimated GF Value™ of MXN979.45.

Key valuation signals for MEX:NSISN:

  • Beta: 0.5829
  • GF Value™: MXN979.45 vs. price of MXN911.11 (7% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score

Get the complete analysis for MEX:NSISN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN911.11
Price
MXN979.45
GF Value